Cardinal Health stock holds near recent highs after strong earnings and guidance

Published on 09/17/2026 at 16:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health stock recently traded around USD 232.65 on the New York Stock Exchange as of September 16, 2026, close to the upper half of its 52-week range. Strong recent earnings growth and guidance support the valuation debate for investors.

Fotorealistisches Pharma-Distributionslager mit Gabelstapler und Mitarbeitern in Dublin Ohio — Cardinal Health Inc. betreibt ein modernes Pharma-Distributionslager in Dublin, Ohio – ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health stock (ISIN US14149Y1082) recently traded around USD 232.65 on the New York Stock Exchange as of September 16, 2026, positioning the shares in the upper half of their 52-week trading range and underlining how much the market is pricing in the company’s earnings momentum.

Earnings growth underpins valuation

The current debate around Cardinal Health centers on whether its recent earnings drivers can sustain the valuation implied by a share price in the low USD 230s. According to Simply Wall St on September 16, 2026, Cardinal Health last closed at USD 232.65 compared with a narrative fair value estimate of USD 270.94, leaving a gap of USD 38.29, or around 16.5 percent below that fair-value mark.

This valuation gap is closely tied to expectations for earnings expansion. As Zacks reported on September 16, 2026, the Zacks Consensus Estimate for Cardinal Health’s fiscal 2027 earnings implies an 11.5 percent rise from the year-ago reported number, highlighting that analysts are still baking in double-digit earnings growth despite regulatory headwinds.

Regulatory risks and margin pressure

The main counter-factor investors are watching is the impact of US drug-pricing reforms on Cardinal Health’s margins. According to Zacks, Cardinal Health faces risk from Inflation Reduction Act pricing changes, with the central question being whether the company can navigate these shifts without significant margin pressure as it moves through fiscal 2027.

For equity holders, this means the stock’s current level near USD 232.65 needs to be judged against both the 11.5 percent earnings growth implied for fiscal 2027 and the potential compression in profitability if pricing changes bite harder than expected. A valuation that stands more than 15 percent below a fair-value estimate suggests room for upside if management executes well on cost control and contract renegotiations, but it also leaves limited cushion if margins weaken.

Stock trades in upper half of 52-week range

From a market perspective, Cardinal Health stock’s recent price action shows investors are willing to keep the shares near the higher end of their one-year range. An overview cited by Ad-hoc-news on September 16, 2026 indicates that Cardinal Health shares recently traded around USD 232.65, between a recent peak of USD 258.30 and the lower end of their 52-week trading range, underscoring that the stock remains closer to the top than to the bottom of that corridor.

For investors, the combination of a share price roughly 10 percent below a recent high of USD 258.30 and an earnings outlook calling for an 11.5 percent fiscal 2027 increase creates a nuanced risk-reward profile. The upside case relies on Cardinal Health translating its strategic initiatives into real margin resilience as pricing reforms phase in, while the downside case would see the market re-rate the stock if profitability falls short of the growth now expected.

Cardinal Health stock price snapshot

Per the recent data cited by Ad-hoc-news as of September 16, 2026, Cardinal Health stock traded at USD 232.65 on the New York Stock Exchange, with the shares sitting between their 52-week low and a recent peak of USD 258.30 and backed by a market capitalization of around USD 54.60 billion at that same date.